# Veterinary Biomarkers Market > Veterinary Biomarkers Market Research Report Information Animal Type (Companion Animals and Production Animals), Product Type (Biomarkers, Kits & Reagents and Biomarker Readers), Application (Disease Diagnostics, Preclinical Research and Others), Disease Type (Inflammatory & Infectious Diseases, Cardiovascular Diseases, Skeletal Muscle Diseases, Tumor and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 13.2% - **2024:** $ 0.89 Billion - **2025:** $ 1.01 Billion - **2035:** $ 3.5 Billion - **Key Players:** Idexx Laboratories (US), Zoetis (US), Thermo Fisher Scientific (US), Neogen Corporation (US), Virbac (FR), Heska Corporation (US), Randox Laboratories (GB), Biovet (BR), Epitopix (US) **Report ID:** MRFR/MED/10558-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/veterinary-biomarkers-market-12079 --- ## Market Summary ## **Global Veterinary Biomarkers Market Overview** As per MRFR analysis, the Veterinary Biomarkers Market Size was estimated at 0.89 (USD Billion) in 2024. The Veterinary Biomarkers Market Industry is expected to grow from 1.01 (USD Billion) in 2025 to 3.09 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 13.20% during the forecast period (2025 - 2034). Increasing pet ownership and humanization, prevalence of animal diseases, advancements in diagnostics, one health approach demand for personalized medicine, research and development investments, food safety concerns are the key market drivers enhancing the market growth. Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ## **Veterinary Biomarkers Market Trends** The market for veterinary biomarkers has grown at a rapid rate in recent years, largely because pet ownership is on the rise and animals are becoming more and more like people. The veterinary industry has been significantly impacted by this dynamic shift in how people view and care for their pets, creating new opportunities and demands for cutting-edge diagnostic and treatment techniques. The increasing number of pet owners around the world is one of the key factors driving the veterinary biomarkers market. Whether they are dogs, cats, or exotic pets, pets have assimilated into many households. As a result of this tendency, pet owners are more eager than ever to make investments in the health and welfare of their animal companions, which has resulted in a rise in demand for high-quality veterinary care. In order to ensure that these cherished pets receive the finest treatment possible, veterinarians are under growing pressure to make precise and quick diagnoses. Another significant aspect driving the expansion of the veterinary biomarkers market is the humanization of pets. People are still willing to go to considerable efforts to safeguard the health and happiness of their dogs because they continue to view them as members of the family. Consumer expectations have changed as a result, with pet owners now expecting the same level of advanced diagnostics and medical care for their animals as they would for themselves. A profitable market for novel veterinary biomarkers that can help with the early identification, monitoring, and treatment of diseases in pets has been formed as a result of this shift in mentality. Personalized treatment in veterinary care is now possible thanks to the discovery of veterinary biomarkers. Veterinarians may now employ biomarkers to customize treatment strategies for particular dogs, taking into account their distinct genetic make-up and medical history, just like in human medicine. This precision medicine strategy boosts the overall quality of life for pets while also improving treatment outcomes. Thus, driving the Veterinary biomarkers market revenue. ## **Veterinary Biomarkers Market Segment Insights** ### **Veterinary biomarkers Animal Type Insights** The Veterinary biomarkers market segmentation, based on animal type, includes companion animals and production animals. The companion animals segment dominated the market in 2022. The main factor driving the companion animals market is the rise in the number of people who acquire pets as companions, such as dogs, cats, and small mammals. The demand for cutting-edge healthcare solutions, including biomarker-based diagnoses and therapies, has increased as more people decide to bring these animals into their homes. Demand for cutting-edge veterinary treatment is rising as pet owners become more ready to make financial investments in the welfare of their animals. ### **Veterinary biomarkers Product Type Insights** The Veterinary biomarkers market segmentation, based on product type, includes biomarkers, kits & reagents and biomarker readers. The biomarkers, kits & reagents segment dominated the market in 2022. The need for precise and effective diagnostic solutions has increased as diseases in animals, including pets, livestock, and wildlife, are becoming more common. Veterinarians now have the resources they need to make early and precise illness diagnoses because of kits and reagents. The demand for such diagnostic equipment keeps growing as pet owners show greater interest in the health of their animals. ### **Veterinary biomarkers Application Insights** The Veterinary biomarkers market segmentation, based on application, includes disease diagnostics, preclinical research and others. The disease diagnostics segment dominated the market in 2022. Both pet owners and doctors are looking for diagnostic methods that are speedier and more practical. Rapid answers, which are essential for prompt intervention and therapy, are provided by veterinary biomarker tests, especially those created for point-of-care use. The introduction of biomarker-based diagnostic techniques in veterinary offices is being driven by this factor of convenience. **Figure 1: Veterinary Biomarkers Market, by Application, 2022 & 2032 (USD Billion)** **** _Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_ ### **Veterinary biomarkers Disease Type Insights** The Veterinary biomarkers market segmentation, based on disease type, includes inflammatory & infectious diseases, cardiovascular diseases, skeletal muscle diseases, tumor and others. The inflammatory & infectious diseases category generated the most income in 2022. Zoonoses are infectious diseases that can harm humans in addition to harming animals. The [COVID-19](../../../reports/covid-19-diagnostics-market-9710) pandemic has brought attention to the value of keeping an eye on and taking action against infectious diseases in animals to stop potential human transfer. This has raised funding for these illnesses' research and diagnostics, thus boosting the market for veterinary biomarkers. ### **Veterinary biomarkers Regional Insights** By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Veterinary Biomarkers Market dominated this market in 2022 (45.80%). One of the highest rates of pet ownership in the world is in North America. In many households, dogs, cats, and other companion animals are regarded as members of the family. To maintain the health and welfare of pets, there is a high need for improved veterinary treatment, including biomarker-based diagnostics. This is due to the deep emotional connection that exists between pet owners and their animals. Further, the U.S. Veterinary biomarkers market held the largest market share, and the Canada Veterinary biomarkers market was the fastest growing market in the North America region. Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. **Figure 2: VETERINARY BIOMARKERS MARKET SHARE BY REGION 2022 (USD Billion)** **** _Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_ Europe Veterinary biomarkers market accounts for the second-largest market share. The rigorous laws and standards governing animal care are well-known in European nations. The focus on animal welfare increases the demand for precise and trustworthy diagnostic techniques, particularly tests based on biomarkers. Both pet owners and regulatory bodies place a high premium on ensuring the health and welfare of animals, which is helping the market for veterinary biomarkers expand. Further, the German Veterinary biomarkers market held the largest market share, and the UK Veterinary biomarkers market was the fastest growing market in the European region. The Asia-Pacific Veterinary Biomarkers Market is expected to grow at the fastest CAGR from 2023 to 2032. Many economies in the Asia-Pacific region depend heavily on agriculture, and the area is a major producer of cattle. In order to monitor and control infectious diseases and maintain the health of herds and flocks, biomarkers are utilized not just for companion animals but also for livestock. Disease control is becoming more and more necessary as consumer demand for premium meat and dairy products rises. Moreover, China’s Veterinary biomarkers market held the largest market share, and the Indian Veterinary biomarkers market was the fastest growing market in the Asia-Pacific region. **Veterinary biomarkers Key Market Players & Competitive Insights** Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Veterinary biomarkers market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Veterinary biomarkers industry must offer cost-effective items. Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Veterinary biomarkers industry to benefit clients and increase the market sector. In recent years, the Veterinary biomarkers industry has offered some of the most significant advantages to medicine. Major players in the Veterinary biomarkers market, including Zoetis, Virbac, Life Diagnostics, ACUVET BIOTECH, Merck & Co., Inc., IDEXX Laboratories, Inc., MI: RNA Diagnostics Ltd., Mercodia AB, Antech Diagnostics, Inc, Avacta Animal Health Limited and others, are attempting to increase market demand by investing in research and development operations. Zoetis Inc. (Zoetis) is an animal healthcare company that conducts research, develops, produces, and sells drugs, immunizations, and diagnostic equipment for livestock and companion animals. Its products are supplemented by biodevices, genetic diagnostics, and precision cattle husbandry. The company sells vaccines, parasiticides, anti-infective medications, and medicated feed additives among other things. It also offers contract manufacturing services to other parties via its client supply services (CSS) company. The company has manufacturing facilities all over the world, and it sells products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through direct marketing channels and distributors in the Americas, Europe, Africa, Asia, and Australia. The headquarters of Zoetis are located in Parsippany, New Jersey, USA. Idexx Laboratories Inc. (IDEXX) is a medical device firm that focuses on the development, production, and distribution of goods and services for the markets for dairy, poultry, livestock, companion animals, and water testing. The business provides point-of-care veterinary diagnostics, microbiological contaminant testing products (in water), diagnostic and health-monitoring products for livestock and poultry, laboratory diagnostic tools, rapid assay test kits, veterinary reference laboratory diagnostics and consulting services, practice management, and diagnostic imaging systems and services. For the human point-of-care medical diagnostics market, IDEXX also offers a line of blood gas and point-of-care electrolyte analyzers. It offers product distribution across the Americas, Europe, the Middle East, Africa, and Asia-Pacific both directly and via a network of distributors and resellers. The US state of Maine is home to the IDEXX corporate headquarters. **Key Companies in the Veterinary biomarkers market include** **Veterinary biomarkers Industry Developments** _**August 2023:**__Zoetis opened a new building for diagnostics and biodevices research and development._ _**August 2023:**__Zoetis opened a facility in Lincoln, Nebraska, the US._ _**July 2023:**__Zoetis and Numaferm entered into a licensing agreement for the development and production of defined veterinary therapeutics._ _**June 2023:**__IDEXX launched the first veterinary diagnostic test for detecting kidney injury in cats and dogs._ _**January 2022:**__IDEXX announced a series of product and service enhancements to enable veterinary practices to be more efficient, while managing increasing patient volumes._ _**October 2022:**__The National Institutes of Health awarded researchers from Boston University's Chobanian & Avedisian School of Medicine a grant for USD 4.6 million for the creation and validation of novel lung cancer biomarkers._ _**October 2021:**__In order to increase the production of veterinary monoclonal antibodies (mAbs), Zoetis Inc., a multinational animal health firm, announced the expansion of its manufacturing and development facility in Tullamore, Ireland._ ## **Veterinary Biomarkers Market Segmentation** ### **Veterinary biomarkers Animal Type Outlook** ### **Veterinary biomarkers Product Type Outlook** ### **Veterinary biomarkers Application Outlook** ### **Veterinary biomarkers Disease Type Outlook** ### **Veterinary biomarkers Regional Outlook** ## Market Drivers ### Rising Demand for Pet Healthcare The Veterinary Biomarkers Market is experiencing a notable surge in demand for pet healthcare services. As pet ownership continues to rise, owners are increasingly seeking advanced diagnostic tools to ensure the health and well-being of their animals. This trend is reflected in the growing expenditure on veterinary services, which has been projected to reach approximately 30 billion dollars by 2026. The increasing awareness of preventive healthcare and the importance of early disease detection are driving the adoption of biomarkers in veterinary diagnostics. Consequently, this heightened focus on pet health is likely to propel the Veterinary Biomarkers Market forward, as stakeholders seek innovative solutions to meet the evolving needs of pet owners. ### Advancements in Biomarker Research Recent advancements in biomarker research are significantly influencing the Veterinary Biomarkers Market. Innovations in genomics, proteomics, and metabolomics are paving the way for the development of novel biomarkers that can enhance disease detection and monitoring in animals. For instance, the identification of specific biomarkers associated with various diseases has the potential to improve diagnostic accuracy and treatment outcomes. The market is projected to grow at a compound annual growth rate of around 10% over the next few years, driven by these scientific breakthroughs. As research continues to evolve, the Veterinary Biomarkers Market is likely to witness an influx of new products and technologies that cater to the needs of veterinarians and pet owners alike. ### Increasing Focus on Preventive Care The Veterinary Biomarkers Market is witnessing a paradigm shift towards preventive care in veterinary medicine. This shift is largely driven by the recognition that early detection of diseases can lead to better health outcomes for animals. As a result, there is a growing emphasis on the use of biomarkers for routine health screenings and monitoring. The market for preventive veterinary care is expected to expand, with estimates suggesting it could reach 20 billion dollars by 2025. This trend is encouraging veterinary professionals to adopt biomarker-based diagnostics, thereby enhancing the overall quality of care provided to pets. Consequently, the Veterinary Biomarkers Market stands to benefit from this increasing focus on preventive health measures. ### Regulatory Support and Standardization Regulatory support for the development and approval of veterinary biomarkers is playing a crucial role in shaping the Veterinary Biomarkers Market. Governments and regulatory bodies are increasingly recognizing the importance of biomarkers in improving animal health and welfare. Initiatives aimed at streamlining the approval process for biomarker-based diagnostics are likely to foster innovation and encourage investment in this sector. Furthermore, the establishment of standardized protocols for biomarker validation is expected to enhance the credibility and reliability of these diagnostic tools. As regulatory frameworks evolve, the Veterinary Biomarkers Market is poised for growth, as stakeholders gain confidence in the efficacy and safety of biomarker applications. ### Growing Investment in Veterinary Research Investment in veterinary research is a key driver of the Veterinary Biomarkers Market. Increased funding from both public and private sectors is facilitating the exploration of new biomarkers and their applications in veterinary medicine. Research initiatives focused on understanding animal diseases and developing innovative diagnostic tools are gaining momentum. This influx of investment is likely to accelerate the pace of discovery and commercialization of veterinary biomarkers. As a result, the Veterinary Biomarkers Market is expected to expand, with new products entering the market that address unmet needs in animal health diagnostics. The commitment to advancing veterinary research underscores the potential for growth in this dynamic market. ## Future Outlook The Veterinary Biomarkers Market is projected to grow at a 13.2% CAGR from 2025 to 2035, driven by advancements in diagnostics, increasing pet ownership, and rising demand for personalized veterinary care. **New opportunities:** - Development of point-of-care diagnostic devices for rapid biomarker testing. Expansion of biomarker-based personalized treatment plans for companion animals. Investment in AI-driven data analytics for predictive health monitoring in veterinary practices. By 2035, the Veterinary Biomarkers Market is expected to be robust, driven by innovation and increasing demand. ## Segment Insights ### By Animal Type: Companion Animals (Largest) vs. Production Animals (Fastest-Growing) In the Veterinary Biomarkers Market, Companion Animals hold the largest market share, driven by the increasing investment in pet health and the growing awareness among pet owners about preventive healthcare. This segment includes dogs and cats, which are becoming a focal point for veterinary diagnostics, influencing regulatory approvals for new biomarker-based diagnostics tailored to these companion animals. On the other hand, the Production Animals segment is rapidly growing too, mainly due to the rising global demand for food security and the focus on improving livestock health and productivity. As a result, veterinary biomarkers are increasingly being utilized to monitor the health and welfare of production animals, such as cattle, pigs, and poultry. Companion Animals (Dominant) vs. Production Animals (Emerging) Companion Animals, such as dogs and cats, account for a dominant share of the Veterinary Biomarkers Market. This segment benefits significantly from strong consumer spending on pet care as owners seek advanced diagnostics and preventive care solutions. Additionally, the humanization of pets has led to a growing emphasis on the health and well-being of companion animals, spurring innovation in veterinary biomarkers. Conversely, Production Animals represent an emerging opportunity in the market. With an emphasis on sustainable farming and efficient animal husbandry, there is an increasing demand for veterinary biomarkers that can enhance the health and productivity of livestock. This segment's growth is fueled by advancements in biomarker technology and an elevated focus on food safety and quality. ### By Product Type: Biomarkers (Largest) vs. Kits & Reagents (Fastest-Growing) Within the Veterinary Biomarkers Market, the segment distribution reveals Biomarkers as the dominant player, holding the largest market share. Kits & Reagents are emerging quickly, driven by increasing demand for efficient and accurate diagnostic tools in veterinary healthcare. Alongside, Biomarker Readers play a significant role, ensuring accurate interpretation and application of the results, although they hold a relatively smaller share compared to the other two segments. The combination of these products shapes a comprehensive landscape for veterinary diagnostics. Biomarkers (Dominant) vs. Kits & Reagents (Emerging) Biomarkers have established themselves as the cornerstone of the Veterinary Biomarkers Market, providing critical insights into [animal health](https://www.marketresearchfuture.com/reports/animal-health-market-7163) and disease management. Their significance in diagnostics is underscored by ongoing advancements in biomarker discovery and validation, leading to enhanced accuracy in identifying health issues. On the other hand, Kits & Reagents represent an emerging segment fueled by the rising prevalence of zoonotic diseases and the need for rapid testing solutions. These products offer veterinarians user-friendly, quick testing options, which are pivotal in both clinical and field settings, allowing for timely interventions and effective management of animal health. ### By Application: Disease Diagnostics (Largest) vs. Preclinical Research (Fastest-Growing) The Veterinary Biomarkers Market is segmented into three primary applications: Disease Diagnostics, Preclinical Research, and Others. Disease Diagnostics holds a significant share of the market, being a critical component of veterinary practices focused on identifying and managing diseases in animals. On the other hand, Preclinical Research has been gaining traction, specifically as the development of veterinary-specific biomarkers becomes increasingly necessary. While both segments are essential, the division highlights how Disease Diagnostics is currently the largest segment in terms of market share, while Preclinical Research is experiencing a notable increase in its share due to innovations and evolving research methodologies. Disease Diagnostics (Dominant) vs. Preclinical Research (Emerging) Disease Diagnostics remains the dominant segment in the Veterinary Biomarkers Market, primarily due to its extensive application in routine veterinary examinations and the management of various animal diseases. It encompasses a range of tests and diagnostic tools that provide veterinarians with essential insights for effective treatment. In contrast, Preclinical Research is emerging rapidly, driven by advances in biotechnology and an increasing emphasis on animal welfare in research settings. This segment focuses on identifying and validating novel biomarkers that facilitate drug development and safety assessments, which are becoming pivotal in translational research. Together, these segments highlight a dynamic landscape in veterinary applications, where ongoing research and technological advancements are key drivers. ### By Disease Type: Inflammatory & Infectious Diseases (Largest) vs. Tumor (Fastest-Growing) The analysis of the Veterinary Biomarkers Market reveals that Inflammatory & Infectious Diseases hold the largest share, significantly dominating the landscape. This segment has been pivotal due to the increasing prevalence of infectious diseases among pets and livestock, driving demand for effective diagnostic solutions. Meanwhile, the Tumor segment is emerging rapidly, benefitting from heightened awareness and advancements in veterinary oncology, capturing the interest of both practitioners and pet owners alike. Growth trends indicate a robust expansion across the Disease Type segment, primarily driven by advancements in biomarker discovery and technology adoption. Factors contributing to this growth include a rising emphasis on preventive healthcare in animals, increasing pet ownership, and the growing urgency for accurate diagnosis and treatment. With the market becoming more aware of novel tumor biomarkers, this segment is expected to see exponential growth in the coming years. Inflammatory & Infectious Diseases (Dominant) vs. Tumor (Emerging) Inflammatory & Infectious Diseases represent the dominant force in the Veterinary Biomarkers Market, reflecting an urgent need for effective diagnostics in a landscape characterized by rising disease prevalence. This segment leverages established biomarkers for effective disease management and is supported by continuous clinical research. In contrast, the Tumor segment is emerging rapidly, propelled by innovative research in veterinary oncology that has opened new avenues for diagnosing and treating various types of cancers in animals. While the latter is gaining traction among veterinary professionals, the former remains essential due to its extensive applications in diverse animal populations, ensuring a balanced growth prospects across both segments. ## Regional Market Share Analysis ### North America : Leading Market Innovators North America is the largest market for veterinary biomarkers, holding approximately 45% of the global share. The region's growth is driven by increasing pet ownership, rising awareness of animal health, and advancements in diagnostic technologies. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring safety and efficacy in veterinary products. The United States is the primary contributor, with key players such as Idexx Laboratories and Zoetis leading the competitive landscape. The presence of advanced research facilities and a strong focus on innovation bolster the market. Canada also plays a significant role, contributing to the overall growth with its supportive regulatory framework and increasing investments in veterinary healthcare. ### Europe : Emerging Regulatory Frameworks Europe is the second-largest market for veterinary biomarkers, accounting for around 30% of the global market share. The region benefits from stringent regulatory frameworks that promote innovation and ensure high-quality standards in veterinary diagnostics. Increasing pet ownership and a growing emphasis on animal welfare are key drivers of market growth, alongside rising investments in research and development. Leading countries include Germany, France, and the UK, where companies like Virbac and Randox Laboratories are prominent. The competitive landscape is characterized by a mix of established players and emerging startups, fostering innovation. The European Medicines Agency plays a crucial role in regulating veterinary products, ensuring compliance with safety standards, which further enhances market growth. ### Asia-Pacific : Rapidly Growing Market Potential Asia-Pacific is witnessing rapid growth in the veterinary biomarkers market, holding approximately 20% of the global share. The region's expansion is fueled by increasing livestock production, rising pet ownership, and growing awareness of animal health. Additionally, supportive government initiatives and investments in veterinary healthcare infrastructure are significant growth drivers. Countries like China, India, and Australia are leading the market, with a growing number of local and international players entering the space. Companies such as Neogen Corporation and Biovet are expanding their presence, contributing to a competitive landscape that is becoming increasingly dynamic. The region's diverse market needs and regulatory environments present both challenges and opportunities for growth. ### Middle East and Africa : Untapped Market Opportunities The Middle East and Africa region is emerging as a significant player in the veterinary biomarkers market, holding about 5% of the global share. The growth is driven by increasing livestock farming, rising pet ownership, and a growing focus on animal health and welfare. Government initiatives aimed at improving veterinary services and regulations are also contributing to market expansion. Countries like South Africa and the UAE are at the forefront, with a growing number of veterinary clinics and diagnostic laboratories. The competitive landscape is evolving, with both local and international companies, including Heska Corporation and Epitopix, seeking to capitalize on the region's untapped potential. The increasing demand for advanced diagnostic solutions is expected to drive further growth in this sector. ## Competitive Benchmarking The Veterinary Biomarkers Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for rapid and accurate diagnostic tools in veterinary medicine. Key players such as Idexx Laboratories (US), Zoetis (US), and Thermo Fisher Scientific (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Idexx Laboratories (US) focuses on expanding its diagnostic portfolio through technological advancements, while Zoetis (US) emphasizes the development of novel biomarkers for disease detection in pets and livestock. Thermo Fisher Scientific (US) is strategically positioned through its extensive product offerings and commitment to research and development, which collectively shape a competitive environment that is increasingly reliant on technological innovation and strategic collaborations.The market structure appears moderately fragmented, with a mix of established players and emerging companies. Key business tactics such as localizing manufacturing and optimizing supply chains are becoming increasingly prevalent. This approach not only enhances operational efficiency but also allows companies to respond swiftly to regional market demands. The collective influence of major players is significant, as they set industry standards and drive advancements in veterinary diagnostics, thereby shaping the overall market dynamics. In August Idexx Laboratories (US) announced the launch of a new rapid diagnostic test for detecting infectious diseases in companion animals. This strategic move is likely to enhance their product portfolio and strengthen their market position by addressing the growing need for timely diagnostics in veterinary practices. The introduction of this test may also reflect Idexx's commitment to innovation and responsiveness to market needs, potentially increasing their competitive edge. In September Zoetis (US) entered into a partnership with a leading biotechnology firm to co-develop a novel biomarker for early detection of chronic diseases in livestock. This collaboration underscores Zoetis's strategy to enhance its research capabilities and expand its offerings in the livestock sector. By focusing on chronic disease management, Zoetis may position itself as a leader in preventive veterinary care, which is increasingly prioritized by livestock producers. In July Thermo Fisher Scientific (US) expanded its global reach by acquiring a regional diagnostics company in Europe. This acquisition is indicative of Thermo Fisher's strategy to enhance its market presence and diversify its product offerings. By integrating the acquired company's technologies, Thermo Fisher could potentially streamline its operations and improve its competitive positioning in the European veterinary diagnostics market. As of October current competitive trends in the Veterinary Biomarkers Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are playing a crucial role in shaping the landscape, as companies seek to combine resources and expertise to drive innovation. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological advancements, innovation, and supply chain reliability, reflecting a broader shift in the industry towards more sustainable and efficient practices. ## Recent News & Developments _**August 2023:**__Zoetis opened a new building for diagnostics and biodevices research and development._ _**August 2023:**__Zoetis opened a facility in Lincoln, Nebraska, the US._ _**July 2023:**__Zoetis and Numaferm entered into a licensing agreement for the development and production of defined veterinary therapeutics._ _**June 2023:**__IDEXX launched the first veterinary diagnostic test for detecting kidney injury in cats and dogs._ _**January 2022:**__IDEXX announced a series of product and service enhancements to enable veterinary practices to be more efficient, while managing increasing patient volumes._ _**October 2022:**__The National Institutes of Health awarded researchers from Boston University's Chobanian & Avedisian School of Medicine a grant for USD 4.6 million for the creation and validation of novel lung cancer biomarkers._ _**October 2021:**__In order to increase the production of veterinary monoclonal antibodies (mAbs), Zoetis Inc., a multinational animal health firm, announced the expansion of its manufacturing and development facility in Tullamore, Ireland._ ## Report Scope | MARKET SIZE 2024 | 0.8943(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 1.012(USD Billion) | | MARKET SIZE 2035 | 3.498(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.2% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Idexx Laboratories (US), Zoetis (US), Thermo Fisher Scientific (US), Neogen Corporation (US), Virbac (FR), Heska Corporation (US), Randox Laboratories (GB), Biovet (BR), Epitopix (US) | | Segments Covered | Region | | Key Market Opportunities | Advancements in diagnostic technologies enhance precision medicine in the Veterinary Biomarkers Market. | | Key Market Dynamics | Rising demand for rapid diagnostic tools drives innovation and competition in the Veterinary Biomarkers Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of the Veterinary Biomarkers Market by 2035?** A: The Veterinary Biomarkers Market is projected to reach a valuation of 3.498 USD Billion by 2035. **Q: What was the market valuation of the Veterinary Biomarkers Market in 2024?** A: In 2024, the Veterinary Biomarkers Market had a valuation of 0.8943 USD Billion. **Q: What is the expected CAGR for the Veterinary Biomarkers Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Veterinary Biomarkers Market during the forecast period 2025 - 2035 is 13.2%. **Q: Which segment is projected to have the highest valuation in the Veterinary Biomarkers Market by 2035?** A: The Companion Animals segment is projected to reach a valuation of 1.9995 USD Billion by 2035. **Q: What are the key product types in the Veterinary Biomarkers Market?** A: Key product types include Biomarkers, Kits & Reagents, and Biomarker Readers, with Kits & Reagents projected to reach 1.4396 USD Billion by 2035. **Q: Which application segment is expected to dominate the Veterinary Biomarkers Market by 2035?** A: The Disease Diagnostics application segment is expected to dominate, reaching a valuation of 1.9995 USD Billion by 2035. **Q: What is the projected valuation for the Production Animals segment by 2035?** A: The Production Animals segment is projected to reach a valuation of 1.4985 USD Billion by 2035. **Q: Which disease type is anticipated to have a significant market presence in the Veterinary Biomarkers Market?** A: Inflammatory & Infectious Diseases is anticipated to have a significant market presence, projected to reach 1.4196 USD Billion by 2035. **Q: Who are the key players in the Veterinary Biomarkers Market?** A: Key players in the Veterinary Biomarkers Market include Idexx Laboratories, Zoetis, and Thermo Fisher Scientific, among others. **Q: What is the expected growth trend for the Veterinary Biomarkers Market in the coming years?** A: The Veterinary Biomarkers Market is expected to experience robust growth, driven by advancements in diagnostics and a projected CAGR of 13.2% from 2025 to 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/veterinary-biomarkers-market-12079*